Novo Nordisk

Novo Nordisk is a Danish pharmaceutical company known for blockbuster weight-loss and diabetes treatments that has begun a significant push into artificial intelligence for drug discovery and manufacturing. The company has entered a partnership with OpenAI to develop AI capabilities for both drug development processes and factory-floor operations, as part of a broader industry shift toward AI-assisted drug research and discovery. This strategic emphasis on AI occurs at a pivotal moment in pharmaceuticals: the industry has achieved a symbolic milestone with the introduction of the first drug designed with AI assistance, underscoring AI's expanding role in modern drug development. Novo Nordisk's substantial investments in proprietary AI models and manufacturing innovations have become valuable targets for cybercriminals, highlighting the significant competitive and financial stakes of AI technology in pharmaceuticals.